Table 2. Baseline demographic data, presentation of 104 patients with malignant pleural effusion
From: Chemical pleurodesis for malignant pleural effusion: which agent is perfect?
Characteristic | Mean ± SD n | Range % |
|---|---|---|
Age (mean ± SD, range), years | 57.55 ± 9.02 | 22–74 |
Male, n (%) | 50 | 48.1 |
Diabetes mellitus | 24 | 23.7 |
Hypertension | 57 | 54.8 |
Congestive heart failure | 13 | 12.5 |
Hepatic dysfunction | 8 | 7.7 |
Smoker | 28 | 26.9 |
Side of intervention, right, n (%) | 59 | 56.7 |
ECOG score, n (%) | ||
0–2 | 80 | 76.9 |
3–4 | 21 | 20.2 |
Unknown | 3 | 2.9 |
Effusion grade | ||
Small (1–2) | 0 | 0 |
Moderate (3–4) | 6 | 5.8 |
Large (5) | 26 | 25 |
Massive (6) | 72 | 69.2 |
Presenting symptom* | ||
Dyspnea | 104 | 100 |
Chest pain | 32 | 30.7 |
Cough | 39 | 37.5 |
Chest pain and cough | 24 | 23.1 |
Dyspnea score (NYHA) | ||
NYHA II | 9 | 8.7 |
NYHA III | 36 | 34.6 |
NYHA IV | 59 | 56.7 |
Pleural fluid chemistry | ||
Exudate | 104 | 100 |
Mean PH | 7.14 ± 0.22 | 6.87–7.48 |
PH < 7.3 | 93 | 89.4 |
PH ≥ 7.3 | 11 | 10.6 |
Glucose (mg/dl) | 73.3 ± 25.1 | 24–119 |
LDH (IU/L) | 1493± 294 | 586–2862 |
Pleural fluid cytology | ||
WBC (/μl) | 624.2± 58 | 300–2216 |
Mono (%) | 73.4± 3.6 | 65–87 |
Malignant (%) | 12.3± 5.2 | 4–28 |
RBC (/μl) | 19560± 58.7 | 1400–4800 |